ThermoGenesis (KOOL) will merge with privately held TotipotentRx, a cell-based regenerative...

|By:, SA News Editor

ThermoGenesis (KOOL) will merge with privately held TotipotentRx, a cell-based regenerative medicine company. KOOL will issue 12.491M shares worth some $18.6M to TotipotentRx. The deal is expected to close in Q4 and will be "transformative," in the words of KOOL CEO Matthew Plavan. (PR)